[HTML][HTML] Alzheimer's disease drug development pipeline: 2017
J Cummings, G Lee, T Mortsdorf, A Ritter… - Alzheimer's & Dementia …, 2017 - Elsevier
Introduction There is an urgent need to develop new treatments for Alzheimer's disease (AD)
and to understand the drug development process for new AD therapies. Methods We …
and to understand the drug development process for new AD therapies. Methods We …
[HTML][HTML] Alzheimer's disease puzzle: delving into pathogenesis hypotheses
Alzheimer's disease (AD) is a prevalent neurodegenerative disease characterized by both
amnestic and non-amnestic clinical manifestations. It accounts for approximately 60-70% of …
amnestic and non-amnestic clinical manifestations. It accounts for approximately 60-70% of …
[HTML][HTML] Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain
A population of more than six million people worldwide at high risk of Alzheimer's disease
(AD) are those with Down Syndrome (DS, caused by trisomy 21 (T21)), 70% of whom …
(AD) are those with Down Syndrome (DS, caused by trisomy 21 (T21)), 70% of whom …
Role of sugar osmolytes and their nano-counterparts as inhibitors in protein fibrillation
Protein aggregation is responsible for various human diseases, ie Alzheimer's, Parkinson's,
Huntington's as well as cataract. Finding molecular drugs which could prevent protein …
Huntington's as well as cataract. Finding molecular drugs which could prevent protein …
Inhibiting amyloid-β cytotoxicity through its interaction with the cell surface receptor LilrB2 by structure-based design
Inhibiting the interaction between amyloid-β (Aβ) and a neuronal cell surface receptor,
LilrB2, has been suggested as a potential route for treating Alzheimer's disease. Supporting …
LilrB2, has been suggested as a potential route for treating Alzheimer's disease. Supporting …
[HTML][HTML] An overview of the protective effects of chitosan and acetylated chitosan oligosaccharides against neuronal disorders
Chitin is the second most abundant biopolymer on Earth and is mainly comprised of a
marine invertebrate, consisting of repeating β-1, 4 linked N-acetylated glucosamine units …
marine invertebrate, consisting of repeating β-1, 4 linked N-acetylated glucosamine units …
From kinase inhibitors to multitarget ligands as powerful drug leads for Alzheimer's disease using protein‐templated synthesis
V Nozal, A García‐Rubia, EP Cuevas… - Angewandte …, 2021 - Wiley Online Library
Multitarget directed ligands (MTDLs) are arising as promising tools to tackle complex
diseases. The main goal of this work is to create powerful modulating agents for …
diseases. The main goal of this work is to create powerful modulating agents for …
Calcium channel blockers' contribution to overcoming Current drug discovery challenges in Alzheimer's disease
PJ Bernard, D Bellili, L Ismaili - Expert Opinion on Drug Discovery, 2024 - Taylor & Francis
Introduction Alzheimer's disease (AD) is a progressive, irreversible, and multifactorial brain
disorder that gradually and insidiously destroys individual's memory, thinking, and other …
disorder that gradually and insidiously destroys individual's memory, thinking, and other …
Experimental approaches for altering the expression of Abeta‐degrading enzymes
DA Loeffler - Journal of neurochemistry, 2023 - Wiley Online Library
Cerebral clearance of amyloid β‐protein (Aβ) is decreased in early‐onset and late‐onset
Alzheimer's disease (AD). Aβ is cleared from the brain by enzymatic degradation and by …
Alzheimer's disease (AD). Aβ is cleared from the brain by enzymatic degradation and by …
Antiamyloidogenic chemical/biochemical-based designed nanoparticle as artificial chaperone for efficient inhibition of protein aggregation
Protein aggregation is linked to variety of neurodegenerative disorders and other diseases.
Current research involves understanding the mechanism of protein aggregation, inhibiting …
Current research involves understanding the mechanism of protein aggregation, inhibiting …